Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Dec 08, 2023 2:34pm
186 Views
Post# 35775390

RE:RE:RE:RE:RE:RE:Baxter

RE:RE:RE:RE:RE:RE:BaxterIt's all about the absolute risk reduction.  The higher the ARR, the higher the premium pricing for PMX, and the quicker the market penetration for PMX.  These are the most important factors for Baxter. 

I could see a 2 billion dollar valuation if the ARR is 25%. 

I could see a 1.5 billion dollar valuation if the ARR is 20%. 

I could see a 1 billion dollar valuation if the ARR is 15%. 

These are my guesstimates for both PMX and EAA together.  I think we are both in the same ballpark.  It's fine if you want to go into a detailed individual  guesstimate of PMX, EAA, and Dialco to try and get your valuation as high as possible but I just don't see the point in that because then you are going to have to factor in things like the cost of carry for a BBB rated company like Baxter and the timeline for reaching full enrollment, fda approval and peak market penetration etc. 

Now can we all please just sit back and say a little prayer that we did in fact just sign Ohtani.         

 
<< Previous
Bullboard Posts
Next >>